Nicole Heather Moraco, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Sarcoma | 7 | 2016 | 1888 | 0.360 |
Why?
|
Physicians | 1 | 2023 | 4539 | 0.250 |
Why?
|
Neoplasms, Radiation-Induced | 3 | 2013 | 545 | 0.230 |
Why?
|
Retroperitoneal Neoplasms | 2 | 2016 | 334 | 0.190 |
Why?
|
Neoplasm Recurrence, Local | 8 | 2016 | 9122 | 0.180 |
Why?
|
Nerve Sheath Neoplasms | 2 | 2012 | 190 | 0.170 |
Why?
|
Health Care Rationing | 1 | 2022 | 439 | 0.160 |
Why?
|
Standard of Care | 1 | 2022 | 563 | 0.160 |
Why?
|
Neoplasms, Second Primary | 2 | 2013 | 1045 | 0.120 |
Why?
|
Hemangiosarcoma | 2 | 2013 | 228 | 0.120 |
Why?
|
Nomograms | 1 | 2015 | 223 | 0.110 |
Why?
|
Residence Characteristics | 1 | 2022 | 2041 | 0.100 |
Why?
|
Thoracic Wall | 1 | 2013 | 201 | 0.100 |
Why?
|
Leiomyosarcoma | 2 | 2013 | 469 | 0.100 |
Why?
|
Communication | 1 | 2023 | 3722 | 0.080 |
Why?
|
Liposarcoma | 1 | 2011 | 324 | 0.080 |
Why?
|
Quality Improvement | 1 | 2023 | 3730 | 0.080 |
Why?
|
Neurofibromatosis 1 | 1 | 2012 | 558 | 0.070 |
Why?
|
Radiotherapy | 2 | 2011 | 1526 | 0.070 |
Why?
|
Neoplasm Staging | 3 | 2015 | 10961 | 0.060 |
Why?
|
Soft Tissue Neoplasms | 1 | 2013 | 1359 | 0.060 |
Why?
|
Pandemics | 1 | 2023 | 8274 | 0.050 |
Why?
|
Disease-Free Survival | 4 | 2015 | 6871 | 0.050 |
Why?
|
Lymphoma | 1 | 2011 | 1873 | 0.050 |
Why?
|
Head and Neck Neoplasms | 1 | 2015 | 2706 | 0.050 |
Why?
|
Bone Neoplasms | 1 | 2013 | 2521 | 0.050 |
Why?
|
Survival Rate | 4 | 2016 | 12761 | 0.040 |
Why?
|
Health Priorities | 1 | 2022 | 380 | 0.040 |
Why?
|
Neoplasm, Residual | 2 | 2013 | 970 | 0.040 |
Why?
|
Radiotherapy, Adjuvant | 2 | 2013 | 1771 | 0.040 |
Why?
|
Liver Neoplasms | 1 | 2013 | 4216 | 0.040 |
Why?
|
Vulnerable Populations | 1 | 2022 | 685 | 0.030 |
Why?
|
Prognosis | 5 | 2016 | 28901 | 0.030 |
Why?
|
Kaplan-Meier Estimate | 3 | 2012 | 6516 | 0.030 |
Why?
|
Middle Aged | 12 | 2022 | 212863 | 0.030 |
Why?
|
United States | 1 | 2023 | 69573 | 0.030 |
Why?
|
Aged | 10 | 2022 | 162698 | 0.030 |
Why?
|
Viscera | 1 | 2014 | 139 | 0.030 |
Why?
|
Humans | 14 | 2023 | 739398 | 0.030 |
Why?
|
Aged, 80 and over | 6 | 2013 | 57650 | 0.030 |
Why?
|
Follow-Up Studies | 4 | 2016 | 38942 | 0.020 |
Why?
|
Female | 12 | 2022 | 378853 | 0.020 |
Why?
|
Male | 11 | 2022 | 349022 | 0.020 |
Why?
|
DNA Topoisomerases, Type II | 1 | 2011 | 121 | 0.020 |
Why?
|
Dermatofibrosarcoma | 1 | 2010 | 62 | 0.020 |
Why?
|
Tumor Burden | 1 | 2016 | 1904 | 0.020 |
Why?
|
Histiocytoma, Malignant Fibrous | 1 | 2010 | 63 | 0.020 |
Why?
|
Combined Modality Therapy | 2 | 2013 | 8605 | 0.020 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 1 | 2010 | 11410 | 0.020 |
Why?
|
Adult | 9 | 2014 | 213394 | 0.020 |
Why?
|
Retrospective Studies | 5 | 2022 | 76631 | 0.020 |
Why?
|
Critical Care | 1 | 2022 | 2624 | 0.020 |
Why?
|
Boston | 1 | 2022 | 9314 | 0.020 |
Why?
|
New York City | 1 | 2011 | 704 | 0.020 |
Why?
|
Multivariate Analysis | 2 | 2013 | 12237 | 0.020 |
Why?
|
Young Adult | 5 | 2013 | 56255 | 0.020 |
Why?
|
Lung Neoplasms | 1 | 2013 | 12985 | 0.020 |
Why?
|
Fibrosarcoma | 1 | 2010 | 348 | 0.020 |
Why?
|
Extremities | 1 | 2013 | 849 | 0.020 |
Why?
|
Adolescent | 5 | 2013 | 85405 | 0.020 |
Why?
|
Proportional Hazards Models | 2 | 2012 | 12328 | 0.020 |
Why?
|
Healthcare Disparities | 1 | 2022 | 3138 | 0.020 |
Why?
|
Statistics, Nonparametric | 1 | 2012 | 2881 | 0.020 |
Why?
|
Confidence Intervals | 1 | 2012 | 2974 | 0.020 |
Why?
|
Lower Extremity | 1 | 2014 | 1145 | 0.020 |
Why?
|
Breast Neoplasms | 1 | 2013 | 20676 | 0.020 |
Why?
|
Gene Knockdown Techniques | 1 | 2011 | 1654 | 0.020 |
Why?
|
Medical Records | 1 | 2011 | 1413 | 0.020 |
Why?
|
Lymphatic Metastasis | 1 | 2013 | 2897 | 0.020 |
Why?
|
Incidence | 2 | 2016 | 20913 | 0.020 |
Why?
|
Prospective Studies | 3 | 2016 | 53037 | 0.020 |
Why?
|
Cell Adhesion Molecules | 1 | 2011 | 1599 | 0.020 |
Why?
|
Severity of Illness Index | 1 | 2022 | 15511 | 0.010 |
Why?
|
Chemotherapy, Adjuvant | 1 | 2012 | 3453 | 0.010 |
Why?
|
Radiotherapy Dosage | 1 | 2010 | 2872 | 0.010 |
Why?
|
Protein Kinases | 1 | 2011 | 1637 | 0.010 |
Why?
|
Receptor Protein-Tyrosine Kinases | 1 | 2011 | 1659 | 0.010 |
Why?
|
Antigens, Neoplasm | 1 | 2011 | 1977 | 0.010 |
Why?
|
Hospitalization | 1 | 2022 | 10208 | 0.010 |
Why?
|
Oligonucleotide Array Sequence Analysis | 1 | 2011 | 3922 | 0.010 |
Why?
|
Risk Assessment | 2 | 2016 | 23294 | 0.010 |
Why?
|
Neoplasm Metastasis | 1 | 2012 | 4832 | 0.010 |
Why?
|
Up-Regulation | 1 | 2011 | 4205 | 0.010 |
Why?
|
RNA, Small Interfering | 1 | 2011 | 3498 | 0.010 |
Why?
|
Neoadjuvant Therapy | 1 | 2012 | 2688 | 0.010 |
Why?
|
Risk Factors | 3 | 2013 | 71974 | 0.010 |
Why?
|
Survivors | 1 | 2011 | 2280 | 0.010 |
Why?
|
Survival Analysis | 1 | 2013 | 10247 | 0.010 |
Why?
|
Databases, Factual | 1 | 2014 | 7690 | 0.010 |
Why?
|
Age Factors | 1 | 2016 | 18349 | 0.010 |
Why?
|
Muscle, Skeletal | 1 | 2013 | 4920 | 0.010 |
Why?
|
Treatment Outcome | 2 | 2013 | 62693 | 0.010 |
Why?
|
Predictive Value of Tests | 1 | 2011 | 15036 | 0.010 |
Why?
|
Gene Expression Profiling | 1 | 2011 | 9387 | 0.010 |
Why?
|
Apoptosis | 1 | 2011 | 9714 | 0.010 |
Why?
|
Cell Line, Tumor | 1 | 2011 | 16646 | 0.010 |
Why?
|
Prevalence | 1 | 2011 | 15153 | 0.010 |
Why?
|
DNA-Binding Proteins | 1 | 2011 | 9622 | 0.010 |
Why?
|
Genetic Predisposition to Disease | 1 | 2011 | 17384 | 0.010 |
Why?
|
Time Factors | 1 | 2010 | 40050 | 0.000 |
Why?
|
Cohort Studies | 1 | 2011 | 40389 | 0.000 |
Why?
|